Please login to the form below

drug side effects

This page shows the latest drug side effects news and features for those working in and with pharma, biotech and healthcare.

Nektar’s opioid analgesic slammed with FDA panel rejection

High levels of euphoric side-effects from opioid medications have lead to abuse and addiction, which has caused a healthcare crisis to erupt across the US. ... Nektar’s drug avoids these side-effects because – according to the company – its

Latest news

FDA clears SK Life Science’s anti-epileptic drug Xcopri

Significantly reduced the frequency of seizures at all doses studied. Korea-based SK Life Sciences has scored approval from the FDA in the US for its anti-epileptic drug Xcopri, as ... The safety profile of the anti-epilepsy drug does include side
Servier faces manslaughter trial over weight loss drug deaths

Lawyers representing the 2, 684 plaintiffs claim that Servier and the ANSM allowed the drug to remain on the market even though its side effects had been known for several years, ... The side effects caused by Mediator were uncovered by French
Tecfidera successor’s side-effect profile boosts Biogen

One of the biggest issues is that these newer treatments don’t cause the gastrointestinal side-effects frequently seen in patients taking Tecfidera. ... However, that’s not to say patients on the new drug were without side-effects: the most common
ViiV builds case for switching to its two-drug HIV combinations

The TANGO study is intended to show that people with HIV can reduce the number of medicines in their HIV treatment regimen, potentially reducing the risk of side effects and drug ... Injectable option. Meanwhile, ViiV also had an update this week on
ViiV bags EU okay for new two-drug HIV therapy

It claims the two-drug regimens can reduce drug exposure and side effects, as well as improve adherence to therapy while maintaining the same level of efficacy. ... efficacy is non-inferior to a three-drug regimen whilst containing fewer

More from news
Approximately 1 fully matching, plus 107 partially matching documents found.

Latest Intelligence

Where next in Alzheimer’s disease R&D?

Much of this research centred on improving the selectivity of compounds so that they hit the target, M1, without also interacting with similar receptors linked to the intolerable side effects. ... Meanwhile, Karuna Pharmaceuticals has raised $42m to
Redirecting your patient strategy

But when people are dealing with their condition for so long, it is important that you understand how they're actually managing it, how they're using the drug.”. ... These new companies have developed novel business models based on sharing the data and
Choices, choices: the rapidly evolving HIV treatment landscape

IIs are more potent, with fewer side effects and drug interactions and the top reason for prescribing them is their good tolerability profile. ... As patients differ so do their barriers to adherence, whether this be complexity of the dosing regimen,
Patients First

to their thoughts on the impact of drug side effects, these are all areas that pharma is already actively engaged with at some level.
Oncology drugs under AMNOG: part two

The G-BA assesses drugs on four criteria: mortality; morbidity (for example, symptom improvement); quality of life; and adverse events (toxicity and side effects). . ... A natural question to ask is how the benefit finding impacts the final price of a

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest from PMHub

My MS journey: one patient's search for innovation

I’ve also seen a neuro-urologist who deals with bladder problems. The problem is, each specialist may give you a drug which can have unpleasant side effects, causing another layer

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

OPEN Health attend EB World Congress—building on momentum and strength in numbers for epidermolysis bullosa: Ben Speller shares his thoughts on the value of disease specific congresses...
OPEN Health use PR to support clinical trial recruitment: International Clinical Trials Day finds clinical research in the spotlight like never before, with any news coming from the many studies into potential vaccines and treatments for SARS-CoV-2...
Covid-19: what could it mean for the diabetic population?: Steve How and Oli Hudson, of Wilmington Healthcare, assess the scale of the diabetes crisis and how coronavirus might impact on it...